Delivery Order SPE2DE21D0005-SPE2D625F87GE

Award Date 2/20/25
Potential Completion Date 2/25/25
Potential Value $21K
Federal Agency
Medical Supply Chain
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Fixed Price with Economic Price Adjustment
Place of Performance
Canton, MA 02021, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
65
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for a delivery order (SPE2DE21D0005|SPE2D625F52FT) with a ceiling value of $1,239.95, issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Organogenesis Inc., a for-profit medical manufacturer headquartered in Canton, Massachusetts. The contract is for the supply of APLIGRAF, a skin substitute product, to support wound care and tissue regeneration needs across military and veteran healthcare systems. Organogenesis holds several...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts. The $1,239.95 fixed-price contract with economic price adjustment is for the delivery of APLIGRAF, a skin substitute product. Organogenesis, a for-profit manufacturer, has an established track record of supplying specialized medical supplies, including wound care and tissue regeneration solutions, to the...
This federal contract award is to Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts. The contract, valued at $2,479.90, is a delivery order issued under the Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract. The award is for the supply of the APLIGRAF advanced wound care product, a specialized skin substitute and tissue regeneration solution used in medical treatments. The contract does not utilize any set-aside...
This federal contract award, valued at $1,239.95, was issued by the Defense Logistics Agency (DLA) to Organogenesis Inc., a for-profit manufacturer of regenerative medicine products. The contract is a delivery order for APLIGRAF, a skin substitute product. The contract has no set-aside designation, indicating Organogenesis competed as a standard commercial vendor. Organogenesis is a key supplier of advanced wound care, surgical biologics, and tissue regeneration products to federal healthcare...
This federal contract award, with ID SPE2DE21D0005|SPE2D625F83GA, was issued by the Defense Logistics Agency (DLA) to Organogenesis Inc., a for-profit manufacturer and provider of regenerative medical products. The $1,239.95 fixed-price delivery order contract is for the supply of APLIGRAF, a skin substitute product, to support advanced wound care and tissue regeneration needs across military and veteran healthcare systems. Organogenesis holds several significant federal Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Organogenesis Inc., a leading regenerative medicine company specializing in advanced wound care and surgical biologics products. The contract, valued at $8,150.00, is for the delivery of PURAPLY MZ 500MG, a wound care product. Organogenesis holds several significant Indefinite Delivery Vehicles (IDVs) with federal agencies, including a $25 million single-award Indefinite Delivery Contract...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Organogenesis Inc., a regenerative medicine company specializing in advanced wound care, surgical biologics, and tissue regeneration products. The contract, valued at $5,100.00, is for the supply of PURAPLY AM XT 4.91X4.91 medical products. This is not a set-aside contract, indicating Organogenesis competed as a standard commercial vendor. The contract is a fixed-price with economic price...
This federal contract award to Organogenesis Inc. is a $2,200.00 fixed-price delivery order issued by the Defense Logistics Agency (DLA) Troop Support Medical for the product PURAPLY AM XT 4.91X4.91. The award has an ultimate completion date of July 5, 2024 and does not utilize a set-aside designation. Organogenesis Inc. is a leading regenerative medicine company that has been awarded numerous contracts with the Department of Defense (DoD) and Department of Veterans Affairs (VA) to supply...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Organogenesis Inc., a leading regenerative medicine company. The contract, valued at $4,645.00, is for the supply of PURAPLY MZ 500MG, a regenerative wound care product. Organogenesis is a for-profit organization and a manufacturer of goods. The contract does not utilize any set-aside designations. This delivery order is part of a larger $49.5 million multiple-award Indefinite Delivery...
The U.S. Department of Defense's Medical Supply Chain (Defense Logistics Agency Troop Support Medical) has awarded Organogenesis Inc. a $8,500.00 fixed-price delivery order contract (SPE2DE21D0005|SPE2D624F9CS2) for the supply of PURAPLY AM XT 4.91x4.91 medical products. This delivery order is part of Organogenesis' existing $49.5 million multiple-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency for wound care dressings, discs, and medical materials. Organogenesis is...
  • SPE2DE21D0005
    Indefinite Delivery Contract
  • SPE2DE21D0005-SPE2D625F87GE
    Delivery Order

This federal contract award, with an ID of SPE2DE21D0005|SPE2D625F87GE, was issued by the Defense Logistics Agency (DLA) to Organogenesis Inc., a for-profit manufacturer and regenerative medicine company located in Canton, Massachusetts. The $21,384.00 fixed-price delivery order contract is for the supply of PURAPLY SX 6CM X 9CM medical products, which are likely advanced wound care or tissue regeneration solutions used to support medical treatments across military and veteran healthcare programs.

The contract does not have a set-aside designation, indicating Organogenesis competes as a standard commercial vendor. Organogenesis holds several significant federal Indefinite Delivery Vehicles (IDVs) with the Department of Veterans Affairs (VA) and DLA, including a $25 million contract for surgical implants, a $30 million Federal Supply Schedule contract, and a $49.5 million IDC for wound care products. These contract vehicles enable Organogenesis to provide a comprehensive range of regenerative medicine products to the government.

Generated 5/22/25, 8:19 PM